News/Blog Read about our latest news: Early efficacy signals in ovarian cancer patients in ongoing Ph1 trial: Poster reporting findings presented at SITC 2020 Annual Meeting by admin | Nov 17, 2020 | UncategorizedRead Article ENB Therapeutics Announces Successful Completion of the First Dosing Cohort in Phase 1 Clinical Trial of ENB-003 in Combination with Pembrolizumab by admin | Nov 17, 2020 | UncategorizedRead Article IND approval received for lead product ENB-003 by admin | Nov 17, 2020 | UncategorizedRead Article ENB Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ENB-003 in combination with KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors by admin | Feb 4, 2019 | Press ReleasesRead Article ENB Therapeutics Closes Series A Round of Funding by admin | Sep 21, 2018 | Press ReleasesRead Article ENB to present at 2016 Pitch Fest organized by New York Bio by admin | Apr 25, 2016 | UncategorizedRead Article ENB CSO and Co-founder Dr. Sumayah Jamal wins Best-in-show at 1st Pitch Life Science NYC by admin | Apr 25, 2016 | UncategorizedRead Article ENB Therapeutics accepted for presentation at the 2016 HemOnc Today Melanoma Conference in NYC by admin | Apr 25, 2016 | UncategorizedRead Article ENB’s Co-founder and CSO Dr. Sumayah Jamal is accepted into the 2016 Pharma Class of Springboard Health Innovation Hub by admin | Apr 25, 2016 | UncategorizedRead Article ENB Lead Product ENB001 Awarded Orphan Drug Designation by the FDA by admin | Jan 30, 2016 | UncategorizedRead Article « Older Entries
Early efficacy signals in ovarian cancer patients in ongoing Ph1 trial: Poster reporting findings presented at SITC 2020 Annual Meeting by admin | Nov 17, 2020 | UncategorizedRead Article
ENB Therapeutics Announces Successful Completion of the First Dosing Cohort in Phase 1 Clinical Trial of ENB-003 in Combination with Pembrolizumab by admin | Nov 17, 2020 | UncategorizedRead Article
ENB Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ENB-003 in combination with KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors by admin | Feb 4, 2019 | Press ReleasesRead Article
ENB Therapeutics Closes Series A Round of Funding by admin | Sep 21, 2018 | Press ReleasesRead Article
ENB to present at 2016 Pitch Fest organized by New York Bio by admin | Apr 25, 2016 | UncategorizedRead Article
ENB CSO and Co-founder Dr. Sumayah Jamal wins Best-in-show at 1st Pitch Life Science NYC by admin | Apr 25, 2016 | UncategorizedRead Article
ENB Therapeutics accepted for presentation at the 2016 HemOnc Today Melanoma Conference in NYC by admin | Apr 25, 2016 | UncategorizedRead Article
ENB’s Co-founder and CSO Dr. Sumayah Jamal is accepted into the 2016 Pharma Class of Springboard Health Innovation Hub by admin | Apr 25, 2016 | UncategorizedRead Article
ENB Lead Product ENB001 Awarded Orphan Drug Designation by the FDA by admin | Jan 30, 2016 | UncategorizedRead Article
